NCT02257242 - Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

August 22, 2020

Study Completion Date

November 18, 2020

Conditions

Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Mantle-CellLymphoma, Small-CellWaldenstrom MacroglobulinemiaLymphoma, B-Cell, Marginal Zone

Interventions

DRUG

Rituximab

375 mg/m2 I.V. on Day 1 of each cycle

DRUG

Bendamustine

90 mg/m2 I.V. on Day 1 and 2 of each cycle

DRUG

Vincristine sulfate liposome injection

Dose per dose escalation protocol, I.V. on Day 2 of each cycle

Trial Locations (1)

Rhode Island Hospital and The Miriam Hospital, Providence